Bellevue Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Bellevue Asset Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-29	Closed	-$3K	–	600
2021 Q3	$3K	Buy	29 +10	+53%	+$1.17K	﹤0.01%	489
2021 Q2	$3K	Sell	19 -2	-10%	-$226	﹤0.01%	488
2021 Q1	$2K	Sell	21 -3	-13%	-$350	﹤0.01%	612
2020 Q4	$3K	Buy	24 +1	+4%	+$131	﹤0.01%	563
2020 Q3	$2K	Hold	23	–	–	﹤0.01%	583
2020 Q2	$4K	Hold	23	–	–	﹤0.01%	453
2020 Q1	$4K	Buy	23 +13	+130%	+$2.51K	﹤0.01%	432
2019 Q4	$2K	Buy	+10	New	+$1.82K	﹤0.01%	470

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Bellevue Asset Management's RETA Position: Q4 2021 in Review

Bellevue Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 29 shares — an estimated $3K sold.

Bellevue Asset Management first reported a position in RETA in Q4 2019 and held it in 8 quarters. The position peaked at $4K in Q2 2020. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

Bellevue Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
Bellevue Asset Management sold 29 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $3K.
Bellevue Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 8 quarters.
Bellevue Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $4K in Q2 2020.
151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on Bellevue Asset Management's 13F filing for Q4 2021, filed 3 Feb 2022.